ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.
- NCT00153101
- PHASE4
- INTERVENTIONAL
Last updated: 2014-05-20
Purpose of Trial
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.
Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.
This study is for people with
Cardiovascular Diseases
Interventions being studied
Telmisartan
Combination of Telmisartan and Ramipril
Ramipril
Inclusion Criteria:
Coronary Artery Disease: Previous Myocardial infarction(\> 2 days prior to informed consent), or stable or previous unstable angina (\> 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (\> 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Grafting without angina (if surgery performed \> 4 years prior to informed consent) or with recurrent angina after surgery.
Other High Risk:
1. Peripheral Arterial Disease: Previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure ratio \< 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing
2. Previous stroke
3. Transient ischemic Attack \> 7 days and \< 1 year prior to informed consent
4. Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left ventricular hypertrophy, micro or macro albuminuria), or any evidence of previous cardiac or vascular disease.
No definite and specific indication or contraindication for any of the study treatments. Written informed consent.
Exclusion Criteria:
A. Medication use:
1. Inability to discontinue Angiotension Converting Enzyme (ACE) inhibitors or Angiotension 2 receptor antagonists (AIIAs).
2. Patients with known hypersensitivity or intolerance to Angiotension 2 receptor antagonists (AIIAs) or Angiotension Converting Enzyme (ACE)inhibitors.
NOTE: Patients with known intolerance to Angiotension Converting Enzyme inhibitor intolerance ( ACE-I) can be enrolled in the TRANSCEND study.
B. Cardiovascular disease:
1. Symptomatic congestive heart failure.
2. Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve).
3. Constrictive pericarditis.
4. Complex congenital heart disease.
5. Syncopal episodes of unknown etiology \< 3 months before informed consent.
6. Planned cardiac surgery or angioplasty within three months.
7. Uncontrolled hypertension on treatment (i.e.Blood pressure ( BP) \> 160/100).
8. Heart transplant recipient.
9. Strokes due to subarachnoid hemorrhage
C. Other conditions:
1. Significant renal disease defined as:
1. Renal artery stenosis;
2. Creatinine clearance \< 0.6 ml/min or serum creatinine \> 265 umol/L (\> 3.0 mg/dL);
3. Hyperkalemia: potassium \> 5.5 mmol/L.
4. Proteinuria\* (for TRANSCEND only).
2. Hepatic dysfunction as defined by the following laboratory parameters: Serum Glutamate Pyruvate Transaminase( SGPT) Alaninaminotransferase (ALT) or Serum Glutamic Oxaloacetic Transaminase (SGOT) Aspartate aminotransferase (AST) \> than 4 times upper limit of normal or additional criteria for hepatic impairment the upper limit of normal range, total Bilirubin \> 20 umol/L, biliary obstructive disorders.
3. Uncorrected volume depletion or sodium depletion.
4. Primary aldosteronism.
5. Hereditary fructose intolerance.
6. Any other major non-cardiac illness expected to reduce life expectancy or interfere with study participation.
7. Patient is simultaneously taking another experimental drug.
8. Patient with significant disability that precludes regular attendance at clinic for follow-up.
9. Patient has sufficient disability or other incapacity that precludes regular attendance at clinic for follow-up.
10. Unable or unwilling to provide written informed consent.
ELIGIBILITY
Gender: ALL
Age: 55+
Healthy Volunteers: No
100 Locations
Athens
502.373.0256 Boehringer Ingelheim Investigational Site
Alabama, United States
Birmingham
502.373.0251 Boehringer Ingelheim Investigational Site
Alabama, United States
Phoenix
502.373.0182 Boehringer Ingelheim Investigational Site
Arizona, United States
Phoenix
502.373.0188 Boehringer Ingelheim Investigational Site
Arizona, United States
Tucson
502.373.0189 Boehringer Ingelheim Investigational Site
Arizona, United States
Tuscon
502.373.0177 Boehringer Ingelheim Investigational Site
Arizona, United States
Bentonville
502.373.0209 Boehringer Ingelheim Investigational Site
Arkansas, United States
Concord
502.373.0173 Boehringer Ingelheim Investigational Site
California, United States
Harbor City
502.373.0266 Boehringer Ingelheim Investigational Site
California, United States
Loma Linda
502.373.0283 Boehringer Ingelheim Investigational Site
California, United States
Los Angeles
502.373.0180 Boehringer Ingelheim Investigational Site
California, United States
Sacramento
502.373.0175 Boehringer Ingelheim Investigational Site
California, United States
San Diego
502.373.0165 Boehringer Ingelheim Investigational Site
California, United States
San Leandro
502.373.0228 Boehringer Ingelheim Investigational Site
California, United States
Sylmar
502.373.0205 Boehringer Ingelheim Investigational Site
California, United States
West Hills
502.373.0277 Boehringer Ingelheim Investigational Site
California, United States
Bridgeport
502.373.0226 Boehringer Ingelheim Investigational Site
Connecticut, United States
Farmington
502.373.0174 Boehringer Ingelheim Investigational Site
Connecticut, United States
Washington
502.373.0258 Boehringer Ingelheim Investigational Site
District of Columbia, United States
Gainesville
502.373.0179 Boehringer Ingelheim Investigational Site
Florida, United States
Palm Harbor
502.373.0183 Boehringer Ingelheim Investigational Site
Florida, United States
Panama City
502.373.0240 Boehringer Ingelheim Investigational Site
Florida, United States
Tampa
502.373.0171 Boehringer Ingelheim Investigational Site
Florida, United States
Vero Beach
502.373.0282 Boehringer Ingelheim Investigational Site
Florida, United States
Weston
502.373.0214 Boehringer Ingelheim Investigational Site
Florida, United States
Augusta
502.373.0161 Boehringer Ingelheim Investigational Site
Georgia, United States
Augusta
502.373.0193 Boehringer Ingelheim Investigational Site
Georgia, United States
Augusta
502.373.0201 Boehringer Ingelheim Investigational Site
Georgia, United States
Conyers
502.373.0223 Boehringer Ingelheim Investigational Site
Georgia, United States
Sandersville
502.373.0268 Boehringer Ingelheim Investigational Site
Georgia, United States
Savannah
502.373.0245 Boehringer Ingelheim Investigational Site
Georgia, United States
Tucker
502.373.0199 Boehringer Ingelheim Investigational Site
Georgia, United States
Valdosta
502.373.0162 Boehringer Ingelheim Investigational Site
Georgia, United States
Pocatello
502.373.0203 Boehringer Ingelheim Investigational Site
Idaho, United States
Burbank
502.373.0244 Boehringer Ingelheim Investigational Site
Illinois, United States
Chicago
502.373.0272 Boehringer Ingelheim Investigational Site
Illinois, United States
Olympia Fields
502.373.0217 Boehringer Ingelheim Investigational Site
Illinois, United States
Des Moines
502.373.0270 Boehringer Ingelheim Investigational Site
Iowa, United States
Monroe
502.373.0167 Boehringer Ingelheim Investigational Site
Louisiana, United States
Shreveport
502.373.0158 Boehringer Ingelheim Investigational Site
Louisiana, United States
Baltimore
502.373.0247 Boehringer Ingelheim Investigational Site
Maryland, United States
Boston
502.373.0284 Boehringer Ingelheim Investigational Site
Massachusetts, United States
Springfield
502.373.0229 Boehringer Ingelheim Investigational Site
Massachusetts, United States
Wyandotte
502.373.0237 Boehringer Ingelheim Investigational Site
Michigan, United States
Minneapolis
502.373.0208 Boehringer Ingelheim Investigational Site
Minnesota, United States
Minneapolis
502.373.0232 Boehringer Ingelheim Investigational Site
Minnesota, United States
St. Paul
502.373.0231 Boehringer Ingelheim Investigational Site
Minnesota, United States
Biloxi
502.373.0181 Boehringer Ingelheim Investigational Site
Mississippi, United States
Cleveland
502.373.0185 Boehringer Ingelheim Investigational Site
Mississippi, United States
Jackson
502.373.0254 Boehringer Ingelheim Investigational Site
Mississippi, United States
Kansas City
502.373.0195 Boehringer Ingelheim Investigational Site
Missouri, United States
St. Louis
502.373.0207 Boehringer Ingelheim Investigational Site
Missouri, United States
St. Louis
502.373.0239 Boehringer Ingelheim Investigational Site
Missouri, United States
Omaha
502.373.0279 Boehringer Ingelheim Investigational Site
Nebraska, United States
North Las Vegas
502.373.0169 Boehringer Ingelheim Investigational Site
Nevada, United States
Camden
502.373.0157 Boehringer Ingelheim Investigational Site
New Jersey, United States
East Orange
502.373.0202 Boehringer Ingelheim Investigational Site
New Jersey, United States
Newark
502.373.0191 Boehringer Ingelheim Investigational Site
New Jersey, United States
Westwood
502.373.0271 Boehringer Ingelheim Investigational Site
New Jersey, United States
Bronx
502.373.0150 Boehringer Ingelheim Investigational Site
New York, United States
Brooklyn
502.373.0213 Boehringer Ingelheim Investigational Site
New York, United States
Buffalo
502.373.0230 Boehringer Ingelheim Investigational Site
New York, United States
Kingston
502.373.0288 Boehringer Ingelheim Investigational Site
New York, United States
New York
502.373.0238 Boehringer Ingelheim Investigational Site
New York, United States
New York
502.373.0252 Boehringer Ingelheim Investigational Site
New York, United States
New York
502.373.0286 Boehringer Ingelheim Investigational Site
New York, United States
Northport
502.373.0166 Boehringer Ingelheim Investigational Site
New York, United States
Rochester
502.373.0156 Boehringer Ingelheim Investigational Site
New York, United States
Rochester
502.373.0264 Boehringer Ingelheim Investigational Site
New York, United States
Scarsdale
502.373.0227 Boehringer Ingelheim Investigational Site
New York, United States
Westfield
502.373.0163 Boehringer Ingelheim Investigational Site
New York, United States
Williamsville
502.373.0241 Boehringer Ingelheim Investigational Site
New York, United States
Durham
502.373.0273 Boehringer Ingelheim Investigational Site
North Carolina, United States
Winston Salem
502.373.0261 Boehringer Ingelheim Investigational Site
North Carolina, United States
Fargo
502.373.0222 Boehringer Ingelheim Investigational Site
North Dakota, United States
Cincinnati
502.373.0155 Boehringer Ingelheim Investigational Site
Ohio, United States
Cleveland
502.373.0164 Boehringer Ingelheim Investigational Site
Ohio, United States
Dayton
502.373.0168 Boehringer Ingelheim Investigational Site
Ohio, United States
Mansfield
502.373.0159 Boehringer Ingelheim Investigational Site
Ohio, United States
Oklahoma City
502.373.0178 Boehringer Ingelheim Investigational Site
Ohio, United States
Guthrie
502.373.0259 Boehringer Ingelheim Investigational Site
Oklahoma, United States
Oklahoma City
502.373.0154 Boehringer Ingelheim Investigational Site
Oklahoma, United States
Tulsa
502.373.0152 Boehringer Ingelheim Investigational Site
Oklahoma, United States
Portland
502.373.0243 Boehringer Ingelheim Investigational Site
Oregon, United States
Erie
502.373.0265 Boehringer Ingelheim Investigational Site
Pennsylvania, United States
Philadelphia
502.373.0153 Boehringer Ingelheim Investigational Site
Pennsylvania, United States
Sellersville
502.373.0274 Boehringer Ingelheim Investigational Site
Pennsylvania, United States
Charleston
502.373.0184 Boehringer Ingelheim Investigational Site
South Carolina, United States
Columbia
502.373.0248 Boehringer Ingelheim Investigational Site
South Carolina, United States
Dallas
502.373.0172 Boehringer Ingelheim Investigational Site
Texas, United States
Dallas
502.373.0187 Boehringer Ingelheim Investigational Site
Texas, United States
Dallas
502.373.0219 Boehringer Ingelheim Investigational Site
Texas, United States
Dallas
502.373.0275 Boehringer Ingelheim Investigational Site
Texas, United States
Fort Worth
502.373.0221 Boehringer Ingelheim Investigational Site
Texas, United States
Houston
502.373.0206 Boehringer Ingelheim Investigational Site
Texas, United States
Houston
502.373.0234 Boehringer Ingelheim Investigational Site
Texas, United States
Houston
502.373.0280 Boehringer Ingelheim Investigational Site
Texas, United States
Burke
502.373.0249 Boehringer Ingelheim Investigational Site
Virginia, United States
Seattle
502.373.0281 Boehringer Ingelheim Investigational Site
Washington, United States
Milwaukee
502.373.0212 Boehringer Ingelheim Investigational Site
Wisconsin, United States
Primary Contact(s)
Boehringer Ingelheim
Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at
ClinicalTrials.gov